<DOC>
	<DOCNO>NCT02085603</DOCNO>
	<brief_summary>This study design ass whether drug call Saracatinib helpful control bone pain cancer . The investigator know , half patient study receive drug half get placebo . Saracatinib drug try patient many different form cancer . It seem effect bone investigator hope effect cancer spread bone .</brief_summary>
	<brief_title>SarCaBon : A Randomised Phase II Trial Saracatinib Versus Placebo Cancer-induced Bone Pain</brief_title>
	<detailed_description>Controlling cancer pain cancer patient difficult cancer respond radiotherapy chemotherapy sometimes sideeffects strong painkiller , like morphine , limit dose drug give . The investigator evidence molecule call Src involve development cancer-induced bone pain . This study use drug , saracatinib target Src see give patient reduce pain cancer bone . The investigator compare saracatinib placebo 4 week period estimate 62 patient . The investigator measure whether pain patient report less saracatinib placebo . The investigator also measure many painkiller people take saracatinib/placebo , pain threshold change , pain-related symptom quality life improve saracatinib direct effect rate cancer break bone .</detailed_description>
	<mesh_term>Saracatinib</mesh_term>
	<criteria>Able give write informed consent willing follow study protocol . Age ≥ 16 year . Cytologically histologically confirm solid tumour know primary site multiple myeloma painful bone metastases poor control bone pain spite pain medication include opioids WHO performance status ≤ 2 Baseline BPISF score pain average ≥ 4 ≤ 9 010 numerical scale record least two separate day use BPISF Adequate baseline haematological , hepatic renal function , define follow : Absolute neutrophil count ≥ 1.5 x 109/L Haemoglobin &gt; 9.0 g/dL ( transfusion ) Platelet count ≥ 100 x 109/L Bilirubin ≤ 1.5 x ULN ALT AST ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastasis ) Creatinine ≤ 1.5 x ULN Ability take absorb oral medication . Female patient childbearing potential ( i.e . premenopausal female , female menopausal &lt; 1 year surgically sterilize ) must provide negative pregnancy test ( serum ) ≤ 7 day study treatment begin must agree practice effective contraceptive measure ( oral contraceptive pill , intrauterine device diaphragm spermicide ) plus condom study 30 day last dose saracatinib . Male patient partner childbearing potential ( use acceptable highly effective method contraception ) pregnant partner must use effective contraceptive measure ( see 8 ) plus condom study 3 month last dose saracatinib . Patients abstain sperm donation study 3 month last dose saracatinib . Life expectancy &lt; 3 month . Previous plan radiotherapy site pain . Unstable cardiac disease last 3 month . History interstitial lung disease ( bilateral , diffuse parenchymal lung disease ) view know saracatinibrelated pneumonitis . Unable discontinue medication know moderate potent inhibitory effect CYP3A4 , substrate CYP3A4 . Concomitant cytotoxic chemotherapy unless establish maintenance treatment &gt; 6 week ( clinical trial ) . Unable understand write spoken English primary outcome dependent completion BPISF questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>advanced solid malignancy</keyword>
</DOC>